# US 2018/0021361 A1 · Combination drug treatment for hepatitis c infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021361 A1
- Document ID: US20180021361A1
- Status: Published application
- Kind: A1
- Application number: 15/656,872
- Filed: 2017-07-21
- Published: 2018-01-25
- Earliest claimed: 2016-07-22
- Assignees: Janssen Pharmaceuticals, Inc.; Achillion Pharmaceuticals, Inc.
- Applicants: Janssen Pharmaceuticals, Inc.; Achillion Pharmaceuticals, Inc.
- Inventors: Maria Gloria Beumont; Lieve Bijnens; Lawrence M. Blatt; Sushmita Mukherjee Chanda; John Fry; Eugene Jans; Thomas Naoki Kakuda; Sivi Mahadevan; Roel Mertens; Gaston Rafael Picchio; Alex Van Dijck; Peter Van Remoortere; David Apelian; Dawei Chen; Milind Deshphande; James Hui; Avinash Phadke
- Web page: https://patentgrep.com/patent/US20180021361A1

## CPC

- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.

## Claims

### Claim 1

A method of treating HCV in a patient having HCV of genotype 1, genotype 2, genotype 4, genotype 5, or genotype 6 comprising administering to the patient a substantially simultaneous combination of an effective amount of Compound (I) (Simeprevir), Compound (II) (Odalasvir), and Compound (III) or independently a pharmaceutically acceptable salt, hydrate or solvate thereof:

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has HCV genotype 1 or genotype 1a

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient has HCV genotype 2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient has HCV genotype 4.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient has HCV genotype 5.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient has HCV genotype 6.

### Claim 7 (depends on 1)

The method of claim 1, further comprising first determining the HCV genotype in the patient, and then administering the drug combination to the patient.

### Claim 8 (depends on 7)

The method of claim 7, comprising administering the combination to a patient having HCV genotype 1 or genotype 1a.

### Claim 9 (depends on 7)

The method of claim 7, comprising administering the combination to a patient having HCV genotype 2.

### Claim 10 (depends on 7)

The method of claim 7, comprising administering the combination to a patient having HCV genotype 4.

### Claim 11 (depends on 7)

The method of claim 7, comprising administering the combination to a patient having HCV genotype 5.

### Claim 12 (depends on 7)

The method of claim 7, comprising administering the combination to a patient having HCV genotype 6.

### Claim 13 (depends on 1)

The method of claim 1 that does not include administering interferon, PEGylated interferon, or ribavirin to the patient.

### Claim 14 (depends on 1)

The method of claim 1, wherein the patient is a treatment naïve patient.

### Claim 15 (depends on 1)

The method of claim 1, wherein the patient is a treatment experienced patient.

### Claim 16 (depends on 1)

The method of claim 1, wherein the Compounds or pharmaceutically acceptable salts thereof are each administered once per day during the period of administration.

### Claim 17 (depends on 1)

The method of claim 1, wherein the Compounds or pharmaceutically acceptable salts thereof are administered simultaneously.

### Claim 18 (depends on 1)

The method of claim 1, wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered in an amount that is about 50 mg to about 200 mg per day.

### Claim 19 (depends on 18)

The method of claim 18, wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered in an amount that is about 75 mg per day.

### Claim 20 (depends on 1)

The method of claim 1, wherein Compound (II), or a pharmaceutically acceptable salt thereof, is administered in an amount that is about 10 mg to about 200 mg per day.

### Claim 21 (depends on 20)

The method of claim 20, wherein Compound (II), or a pharmaceutically acceptable salt thereof, is administered in an amount that is about 12.5 mg per day or 25 mg per day.

### Claim 22 (depends on 1)

The method of claim 1, wherein Compound (III), or a pharmaceutically acceptable salt thereof, is administered in an amount that is about 200 mg to about 1200 mg per day.

### Claim 23 (depends on 22)

The method of claim 22, wherein Compound (III), or a pharmaceutically acceptable salt thereof, is administered in an amount that is about 800 mg per day.

### Claim 24 (depends on 1)

The method of claim 1, further comprising determining a virologic response to the administration of the compounds.

### Claim 25 (depends on 1)

The method of claim 1, wherein the patient achieves sustained virologic response with an HCV RNA level of less than LLOQ for up to 4 weeks after termination of the administration.

### Claim 26 (depends on 1)

The method of claim 1, wherein the patient achieves sustained virologic response with an HCV RNA level of less than LLOQ for up to 12 weeks after termination of the administration.

### Claim 27 (depends on 1)

The method of claim 1, wherein the patient achieves sustained virologic response with an HCV RNA level of less than LLOQ for up to 24 weeks after termination of the administration.

### Claim 28 (depends on 1)

The method of claim 1, wherein Compound (I), Compound (II), and Compound (III) are administered in a single composition.

### Claim 29 (depends on 28)

The method of claim 28, wherein the composition is a solid dosage form.

### Claim 30 (depends on 29)

The method of claim 29, wherein the solid dosage form is a sprayed dried solid dosage form.

### Claim 31 (depends on 1)

The method of claim 1, wherein the patient is non-cirrhotic.

### Claim 32 (depends on 1)

The method of claim 1, wherein the patient is cirrhotic.

### Claim 33 (depends on 1)

The method of claim 1, wherein the treatment is carried out daily for approximately six weeks.

### Claim 34 (depends on 33)

The method of claim 33, wherein the patient achieves sustained virologic response with an HCV RNA level of less than LLOQ for up to 24 weeks after termination of the administration.

### Claim 35 (depends on 1)

The method of claim 1, wherein the composition includes about 75 mg of Compound I, about 25 mg of Compound II and 800 mg of Compound III.

### Claim 36 (depends on 1)

The method of claim 1, wherein the composition includes about 75 mg of Compound 1, about 12.5 mg of Compound II and 800 mg of Compound III.

### Claim 37 (depends on 1)

The method of claim 1, wherein the patient is a human.
